Patient - 医索

找到约 362 条结果

SACI-0 HR A randomized phase ll trial ofsacituzumab govitecan with or without pembrolizumabin patients with metastatic hormone receptor-positive!HER2-negative breast cancer

医客学院 - 会议报告集

First-line inavolisibplacebo palbociclib fulvestrant(InavoPbo Palbo Fulv) in patients (pts) with PiK3cA-mutated.hormone receptor-positive, HER2-negative locally advancedmetastaticbreast cancer

医客学院 - 会议报告集

DESTINY-Breast07dose-expansion analysis ofT-DXd monotherapy and T-DXd pertuzumab inpatients with previously untreated HER2 mBC

医客学院 - 会议报告集

Datopotamab deruxtecan (Dato-DXd)vs chemotherapy inpreviously-treated inoperable or metastatic hormonereceptor-positive, HER2-negative (HR HER2-) breast cancerPatient-reported outcomes(PROs) from

医客学院 - 会议报告集

Comparison antitumor efficacy Of first-line Of Palbociclib, Ribociclib or Abemaciclib in patients with HR HER2-aBC results of the multicenter, real-world,Italian study PALMARES-2

医客学院 - 会议报告集

Baseline characteristics and efficacyendpoints for patients with node-negativeHR HER2-early breast cancer in NATALEE

医客学院 - 会议报告集

Association of MammaPrint index and 3-yearoutcome of patients in the FLEX Registry trial withHR HER2-early-stage breast cancer treated withchemotherapy with or without anthracycline

医客学院 - 会议报告集

A Randomized, Multicenter, Open-label, Phase lll Trial ComparingAnthracyclines Followed by Taxane Versus Anthracyclines Followedby Taxane Plus Carboplatin as (Neo) Adjuvant Therapy in Patientswith

医客学院 - 会议报告集

Sacituzumab Tirumotecan (sac-TMT; Also Known asSKB264MK-2870)in Combination With KL-A167 (Anti-PD-L1)as First-Line Treatment for Patients With Advanced NSCLCFrom the Phase ll OptiTRoP-Lung01 Study

医客学院 - 会议报告集

Phase lalb trial of zongertinib (Bl 1810631),aHER2-specific tyrosine kinase inhibitor in patients withHER2 aberration-positive solid tumors updatedPhase la data from Beamion LUNG-1, includingprogression-

医客学院 - 会议报告集

今日实时热搜